Struc­ture Ther­a­peu­tics 'en­cour­aged' by 5.4% weight loss with its oral GLP-1, plans for more stud­ies

Last year
R&D

Scoop: Led by for­mer Trump of­fi­cial, Al­te­sa Bio­Sciences rais­es $35M for an­tivi­rals, re­cruits Mon­cef Slaoui to board

Last year
People
Financing

Ex­clu­sive: For­mer Genen­tech duo re­unites to push Sono­ma in­to the clin­ic; Ex-Ma­gen­ta com­mer­cial chief heads to Ed­i­tas

Last year
Peer Review

PTC cuts 25% of its work­force to save mon­ey amid big com­pa­ny re­vamp 

Last year
People

Up­dat­ed: Quince eyes PhI­II tri­al start for rare pe­di­atric dis­ease drug-de­vice as FDA lifts clin­i­cal hold

Last year
FDA+

Stem cell start­up Thym­mune lands $37M from Biden's ARPA-H for im­mune-re­ju­ve­nat­ing ther­a­pies

Last year
Startups

FDA ap­proves ma­jor de­pres­sive drug af­ter re­ject­ing it mul­ti­ple times in past two decades

Last year
FDA+

FDA turns to Fre­se­nius im­ports from EU to help with com­mon can­cer drug short­age

Last year
Manufacturing

Phar­ma com­pa­nies still slow to adopt hy­brid sales rep and dig­i­tal com­mer­cial mod­els – sur­vey

Last year
Marketing

Fed­er­al gov­ern­ment shut­down watch: FDA and in­dus­try prep for like­ly clo­sure Oct. 1

Last year
Pharma
FDA+

Take­da wins FDA ap­proval for self-ad­min­is­tered, sub­cu­ta­neous En­tyvio in ul­cer­a­tive col­i­tis

Last year
FDA+

PBM re­forms: Sen­ate Fi­nance Com­mit­tee lead­ers in­tro­duce an­oth­er bi­par­ti­san bill

Last year
Pharma

Cure­Vac claims de­lay in Ger­man court over al­leged in­fringe­ment of its Covid-19 vac­cine by BioN­Tech a sign in its ...

Last year
Law

J&J Vi­sion looks to the fu­ture with new cor­po­rate cam­paign span­ning gen­er­a­tions of eye health

Last year
Marketing

Bio­nom­ics’ stock sky­rock­ets 340% af­ter PTSD can­di­date pass­es PhI­Ib test

Last year
R&D

FDA ap­proves Am­i­cus' Pom­bil­i­ti + Op­fol­da com­bo ther­a­py for Pompe dis­ease

Last year
FDA+

Kris­ten Hege re­counts an im­por­tant chap­ter in CAR-T his­to­ry — and how that com­pares to an ad­ven­tur­ous coastal ...

Last year
Biotech Voices

CDER tweaks Ozem­pic’s post-mar­ket­ing la­bel to in­clude risk for GI dis­or­der

Last year
Pharma

J&J’s chal­lenge to As­traZeneca in lung can­cer takes flight with PhI­II PFS win

Last year
R&D

Im­muno­van­t's $450M; On­copep­tides re­assess­es Pepax­ti strat­e­gy in Eu­rope; Ake­bia re­sub­mits kid­ney drug

Last year
News Briefing

BioN­Tech re­it­er­ates pres­ence in Africa; WuXi eyes first Chi­nese vac­cine plant; Chi­nese drug­mak­er blocks FDA checks

Last year
Manufacturing

Bio­gen’s R&D prun­ing hits dig­i­tal health as biotech scraps 23,000-per­son cog­ni­tive study with Ap­ple

Last year
Health Tech

Mer­ck to par­tic­i­pate in Medicare ne­go­ti­a­tions process 'un­der protest,' fol­low­ing at least three oth­ers

Last year
Pharma

GSK's Vi­iV to lean on long-act­ing HIV port­fo­lio ahead of do­lute­gravir patent ex­pi­ra­tion

Last year
Pharma
First page Previous page 272273274275276277278 Next page Last page
A service from the Financial Times